Search results: (10000)
News Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
News Teriflunomide under the microscope in studies and practice
Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?
News Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis - BE READY Study Results
The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.
News Potential, Benefits and Proper Use of Probiotics in the Treatment of Acute Gastroenteritis in Children
Clinical studies and experiences from clinical practice have shown the benefits of administering probiotics in the treatment of acute gastroenteritis in children. Pediatrician Dr. Natália Szitányi summarizes the possibilities and rationale for their use in this indication.
News Tofacitinib Helps Restore Intestinal Epithelial Barrier
The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of ulcerative colitis, but its effect on the intestinal epithelium remains a subject of research. The objective of the study presented below was to determine how tofacitinib aids in the repair of the cytokine-damaged intestinal epithelial cell barrier.
News Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children
Children are frequent carriers of pneumococci, which can cause both common non-invasive and more severe, life-threatening invasive pneumococcal diseases, especially in children under 1 year of age and in people over 65 years old. Almost a year ago, a pediatric indication for a 15-valent pneumococcal vaccine was approved, which is enriched with 2 new serotypes and, according to study results, appears to be potentially more effective even in protecting against serotype 3. So what are the vaccination options for healthy immunocompetent children, and what benefits does this vaccine offer for premature infants? Professor Roman Chlíbek, chair of the Czech Vaccinology Society ČLS JEP, answered these questions in his presentation at the June Interdisciplinary Conference of PLDD.
News Parenteral Nutrition in Oncological Patients in Current ESPEN Recommendations
The current guidelines of the European Society for Clinical Nutrition and Metabolism (ESPEN) address nutritional care in oncological patients − current knowledge is summarized in a total of 43 recommendations, from which we select some key points, focusing primarily on parenteral nutrition in these patients.
News Reasons for Nonadherence to Statin Therapy - Survey Results Among Patients
Adherence to statin therapy remains suboptimal despite its proven benefits in reducing cardiovascular risk in individuals with dyslipidemia. Recently published survey results conducted among patients prescribed statins have identified barriers preventing proper adherence to this treatment.
News How and What the National AATD Register Benefits Experts and Patients
Given that alpha-1-antitrypsin deficiency (AATD) is still not receiving enough attention, it is necessary to raise professional awareness of this hereditary disease by all means. This is also one of the goals of the National AATD Register, which collects patient data to monitor the progression of the disease, identify the most suitable prognostic markers, and monitor the presence or progression of other organ impairments in these patients.
News Safety of Dabigatran According to a Meta-Analysis of 7 Randomized Controlled Trials
Dabigatran is a direct thrombin inhibitor from the group of direct oral anticoagulants (DOACs), developed as an alternative to vitamin K antagonists. The aim of the recently published meta-analysis was to compare the risk of bleeding, fatal adverse events, and mortality in patients treated with dabigatran and conventional therapy.
News INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines
What examinations should be conducted when suspecting hypertrophic cardiomyopathy, a hereditary disease caused by mutations in genes encoding cardiac muscle proteins? What is the subsequent procedure for monitoring patients and their at-risk relatives? The comprehensive infographic summarizes the current recommendations of American professional societies.
News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations
Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.
News Programmed Cell Death as a Therapeutic Target in Chronic Lymphocytic Leukemia
One of the key steps in malignant transformation is the disruption of apoptosis. Tumor cells exploit a variety of mechanisms that allow them to evade programmed cell death. Among the drugs targeting apoptosis pathway regulators is venetoclax, a Bcl-2 protein inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Since August 2021, venetoclax in combination with obinutuzumab can newly be used as a reimbursed therapy for previously untreated patients with CLL who are not suitable for fludarabine administration.
News Long-term treatment of ozanimod in patients with moderate to severe ulcerative colitis
The immunosuppressive ozanimod was approved for the treatment of ulcerative colitis (UC) based on the results of the phase III clinical trial True North. An open-label study followed this and previous clinical evaluations, focusing particularly on the efficacy of long-term use of ozanimod. What insights did the subsequent monitoring bring?
News Primum non nocere applies not only in medicine: an ecological look at inhalers
According to estimates from the World Health Organization (WHO), around 65 million people worldwide suffer from mild to moderate forms of chronic obstructive pulmonary disease (COPD). The cornerstone of therapy is the inhalation administration of bronchodilator drugs. While there is no doubt that this therapy helps patients, what impact do the propellants in inhalation systems have on the global climate? And is there a sensible solution to this problem?
News Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization of therapy based on the presence of specific tumor cell mutations is therefore crucial for choosing the optimal therapy for these patients. One of the targeted treatment options for patients with NSCLC with an activating mutation in the epidermal growth factor receptor (EGFR) gene is osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI). We present a case study of a patient with NSCLC treated with osimertinib after disease progression due to a secondary EGFR T790M mutation resulting from afatinib therapy. The described case well illustrates the role of osimertinib in the treatment of NSCLC with secondary EGFR T790M mutation.
News “Think about the thyroid gland during pregnancy,” reminds awareness campaign
Thyroid disorders can endanger the health of both the fetus and the mother. Sometimes, however, the problem only manifests during pregnancy, and the expectant mother or her doctor might not notice it amidst other ongoing changes. The issue was highlighted by an event called “Thyroid Week,” which took place in the Czech Republic during the last week of May 2020.
News Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP was released. Let's take a look at what changes it has brought compared to the previous version in the treatment of metastatic non-small cell lung cancer (NSCLC) with a driver mutation in the ALK gene.
News Benefit of Adding Erdosteine to Maintenance Treatment of COPD
Erdosteine is a mucoactive drug with anti-inflammatory, antioxidant, and anti-adhesive effects against bacteria, commonly used in the treatment of chronic obstructive pulmonary disease (COPD). In August 2022, another post-hoc analysis of the RESTORE study was published, evaluating the impact of its addition to COPD maintenance treatment on the incidence and severity of exacerbations and quality of life in patients with GOLD2 and GOLD3 grade bronchial obstruction.
News Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?
The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of moderately to severely active ulcerative colitis (UC). Its efficacy and safety in this indication have previously been investigated in randomized placebo-controlled trials. However, the study discussed below examined the drug's impact on the endoscopic and histological progression of the disease and fecal calprotectin levels.
News COMMENTARY FROM PRACTICE: On Some Aspects of Care for Patients with Parkinson's Disease
What issues do we still encounter in the diagnosis and treatment of Parkinson's disease even today, despite medical advancements? How to fine-tune the management of care for these patients, facilitate their path to effective therapy, and improve their quality of life using current possibilities? What can their treating neurologist do for them, when is it necessary to consult a specialized center without delay, and how to mitigate the stigmatization associated with this disease? These aspects are also considered in the following commentary from practice.
News Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene
PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
News Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used functional tests as the main tool for monitoring the progression of lung disease. Now we are moving further. Quantitative CT examination is even more advantageous in terms of assessing clinical development.
News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab
Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.
News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL – results from the open part of the ECHELON-3 study
The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).